Network Meta-Analysis Finds TREMFYA ® Ranks Highest for Skin Clearance in Active Psoriatic Arthritis
Dr. Terence Rooney, Vice President, Rheumatology & Maternal-Fetal Immunology Disease Area Leader at Janssen discusses Janssen’s announcement of a comprehensive Network Meta-Analysis (NMA) at Maui Dermatology which concluded that TREMFYA ® (guselkumab) ranked highest for the overall level of skin clearance and showed positive joint efficacy among all advanced therapies approved for the treatment of active psoriatic arthritis (PsA). He talks about what this new data means for patients and why understanding the landscape of treatment options in active PsA is important for physicians making decisions about patient care.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Arthritis. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Arthritis and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Arthritis?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Terence Rooney, M.D., is Vice President, Rheumatology and Maternal-Fetal Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in the rheumatology and maternal-fetal disease area, overseeing innovative compounds across multiple phases of development.
Terence received his medical degrees from the Royal College of Surgeons in Ireland. During 10 years of academic clinical practice at teaching hospitals in Dublin, he completed postgraduate training in Rheumatology and Internal Medicine. His clinical/translational research fields of interest included rheumatoid arthritis biomarkers for the evolving targeted therapy era, in which he acquired a doctoral degree. He completed a post-fellowship attachment at the University of California San Francisco Division of Rheumatology before transitioning to work full time in pharmaceutical research and development.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
